Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 plus tamoxifen in molecularly stratified hormone receptor-positive HER2-negative advanced breast cancer
2014-000599-24Phase 2Completed
- Sponsor
- Universitätsmedizin Essen
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of buparlisib and tamoxifen in breast cancer (3 arms), sponsored by Universitätsmedizin Essen. Primary endpoint: Progression-free survival rate in the full population at 6 months. Started Sep 2014; status: completed.
02
Drugs
buparlisibtamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-000599-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000599-24.